

Docetaxel CHAARTED

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No benefit observed

Serious and disabling adverse effects



Other adjustments



Docetaxel CHAARTED

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Experimental Arm: Docetaxel + ADT (androgen deprivation therapy)

Control Arm: ADT

